US Biosimilars Need Access In Exchange For Industry Commitment
Biosimilars Forum’s Julie Reed Urges Other Stakeholders In The Market To Step Up
Executive Summary
As the dust settles after a wave of fresh adalimumab biosimilar launches, the US Biosimilars Forum’s executive director Julie Reed talks to Generics Bulletin about how other stakeholders need to step up to meet industry’s commitment to the sector – as well as how PBMs are distorting the market and streamlined regulation is needed to drive competition.